百利天恒：T-Bren（HER2ADC）被纳入突破性治疗品种名单

Core Viewpoint - The company, BaiLi TianHeng (688506.SH), announced that its innovative biopharmaceutical T-Bren (HER2ADC) has been included in the list of breakthrough therapies for patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed prior first-line anti-HER2 treatment and first-line standard chemotherapy [1] Group 1 - T-Bren is recognized for its best-in-class potential and has demonstrated significant anti-tumor efficacy in clinical trials [1] - The company is currently conducting 14 clinical trials for T-Bren, covering multiple HER2-positive tumor indications both domestically and internationally [1]